Gilead acquires CAR-T specialist Arcellx for $7.8bn
Gilead has agreed to acquire Arcellx in a deal worth $7.8bn, as the drugmaker looks to add a CAR T-cell therapy for blood cancer treatment on the cusp of approval to its portfolio. As per the agreement, Gilead will pay…









